AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Getting closer to the market
Updates
20/11/19 Financing i...A €2.6m non-dilutive issue
15/10/19 LatestCooperation agreement with the US Dep...
10/09/19 EarningsH1 19: no surprise
10/07/19 Financing i...Warrants to existing shareholders
19/06/19 LatestA commercial success
18/04/19 EPSWe have increased the total number of s...
18/03/19 EPSWe have only fine-tuned our numbers aft...
18/03/19 NAVThe SOTP goes down a tick after the dilu...
18/03/19 DCFThe DCF goes up, despite the increased ...
15/03/19 EarningsSlowly but surely
04/02/19 Financing i...Some extra non-dilutive financing
24/12/18 EPSThe new number of shares has been adju...
24/12/18 NAVThe lower NAV per share stems from the...
24/12/18 DCFThe lower NAV per share stems from the...
21/12/18 LatestSuccess of the capital increase
29/11/18 TargetOur target price is revised downward on t...
29/11/18 EPSOur forecasts have not changed. The hig...
29/11/18 NAVOur NAV valuation is adjusted one the on...
29/11/18 DCFOur forecasts remain unchanged. The hig...
28/11/18 Financing i...A €3.9m capital increase
22/11/18 LatestExcellent news: production has resumed
23/10/18 Other newsBond conversion
03/10/18 EPSOur EPS forecasts only move marginally i...
03/10/18 NAVOur SOTP valuation goes down in line wit...
03/10/18 DCFOur DCF valuation goes quite substantial...
27/09/18 EarningsH1 18: insignificant; some more time nee...
05/09/18 EPSWe have fine-tuned our numbers in the b...
05/09/18 NAVWe have adjusted our numbers to take in...
05/09/18 DCFOur DCF valuation goes up quite signific...
13/07/18 Financing i...A convertible bond and potential options f...
17/05/18 LatestBusiness update
22/03/18 EarningsOn its way to reach the market…
14/02/18 Financing i...A convertible bond and options for existin...
03/02/18 Other newsOrphan disease status for Zeneo® Midaz...
Target
Upside 400%
Price (€) 2.04
Market Cap (€M) 37.6
Perf. 1W: -18.4%
Perf. 1M: -35.8%
Perf. 3M: 37.8%
Perf Ytd: 69.2%
10 day relative perf. to stoxx600: -28.8%
20 day relative perf. to stoxx600: -32.2%